<\/p>\n Clinical research team in thoracic oncology: <\/em><\/p>\n <\/p>\n <\/em><\/p>\n <\/p>\n <\/p>\n <\/p>\n \n From left to right at the top:<\/em><\/p>\n From left to right below:<\/em><\/p>\n People not shown in the photo:<\/p>\n The team works in collaboration with several research laboratories including:<\/p>\n This clinical research work is supported by the clinical investigation center<\/a>-Inserm 1413 of Nantes and the clinical research promotion unit of the Nantes University Hospital.<\/p>\n Domains of expertise (to access the different studies, click on the pathology) You will find below a non-exhaustive list of clinical research studies currently being conducted by our teams<\/p>\n Severe Asthma<\/p>\n<\/div>\n Treatment with anti-CRTH2 antibodies<\/strong>: Severe asthma patients over 12 years of age, with or without maintenance treatment with oral corticosteroids, non-smokers – NARACAS <\/strong> \u00ab Assessing the Expression and the Activity of Rac1 Protein in the Airway Smooth Muscle of Asthmatic Patient\u00bb <\/em>: <\/strong>Severe asthmatic patients over 12 years old, non-smokers, a bronchial fibroscopy is required. -GANA <\/strong>\u00ab Genetic study of familial forms of non-atopic asthma \u00bb : <\/em>genealogical survey of severe non-allergic asthma patients, aged over 12 years. -BENRAPRED<\/strong> \u00ab <\/em>Predictive Signature of Response to Benralizumab \u00bb : <\/em>Severe asthma patients over 18 years of age requiring initiation of Benralizumab with 3 prior exacerbations within 1 year. Emphysema \/ COPD<\/p>\n<\/div>\n -Therapeutic trial with an anti-TSLP antibody<\/strong>: patients with moderate to very severe COPD over the age of 40. –Non-invasive ventilation:<\/strong>“Evaluation of respiratory assistance in patients with chronic obstructive pulmonary disease (COPD) after an acute exacerbation”: Adult patients hospitalized for an exacerbation of their COPD Thoracic cancers (lung cancer, mesothelioma, neuroendocrine tumors)<\/p>\n<\/div>\n – CA209-73L0084 (BMS)<\/strong> “Study of Nivolumab and Ipilimumab in untreated patients with non-operable stage 3 non-small cell lung cancer (CheckMate73L). – IFCT-1805 ELDERLY (IFCT)<\/strong>“Study of atezolizumab in elderly patients with advanced non-small cell lung cancer receiving carboplatin and paclitaxel chemotherapy – ZEAL1\/ 213400 (GSK)<\/strong> “Randomized, double-blind, multicenter, Phase III study evaluating Niraparib plus Pembrolizumab in maintenance versus placebo plus Pembrolizumab in stable or responder stage IIIv or IV NSCLC patients after first-line platinum-based chemotherapy plus Pembrolizumab.” – PDC-Lung-101 (PDC-LINE)<\/strong> \u00ab Evaluation la s\u00e9curit\u00e9 et l\u2019immunog\u00e9nicit\u00e9 du vaccin anti-cancers th\u00e9rapeutique PDC*lung chez des patients atteints de cancers pulmonaire \u00e0 non petite cellules stade pr\u00e9coce ou m\u00e9tastatique. \u00bb – ACT16849 (SANOFI)<\/strong> “A multi-centre, non-randomised, open-label, multi-cohort, phase 2 study evaluating the clinical benefit of SAR444245 (THOR-707) in combination with other cancer therapies for the treatment of patients with lung cancer or pleural mesothelioma.” – MK3475-A86 (MSD) <\/strong>“A phase 3, randomised, open-label clinical trial to investigate the pharmacokinetics and safety of subcutaneous pembrolizumab plus chemotherapy Versus intravenous pembrolizumab plus chemotherapy as first-line treatment in participants with non-small cell lung cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04956692<\/a><\/p>\n – BGB-A317-A1217-302 (BEIGENE)<\/strong> \u00ab Randomised, double-blind, phase 3 study of BGBA1217, an anti-TIGIT antibody, in combination with tislelizumab compared to pembrolizumab in patients with untreated advanced, unresectable and metastatic non-small cell lung cancer selected for PD-L1″ –MARIPOSA \/73841937NSC3003 (JANSSEN)<\/strong>” Randomized 1st<\/sup> line study in patients with locally advanced or metastatic EGFR-mutated NSCLC, evaluating the combination of JNJ-61186372 (Amivantamab) and Lazertinib (3rd<\/sup> generation TKI), versus monotherapy with Lazertinib or Osimertinib ” – PAPILLON \/ JRD 61186372NSC3001 (JANSSEN) <\/strong>\u00ab<\/sup> Randomized, open-label, phase 3 study evaluating in first-line locally advanced or metastaticNSCLC patients with an EGFR exon 20 insertion, a combination of Amivantamab and Carboplatin-Pemetrexed, versus Carboplatin-Pemetrexed chemotherapy alone. – EFC15858 \/ CARMEN-LC03 (SANOFI)<\/strong>“Randomized, open-label, phase 3 study evaluating Docetaxel versus SAR408701 in CEACAM5-positive advanced or metastatic non-squamous NSCLC patients – HUDSON \/ D6185C00001 (ASTRA ZANECA)<\/strong> “Immunotherapy (Umbrella trial, multiple treatment options:) Olaparib, Durvalumab, Savotinib, treatment under study)” – SAPPHIRE (Mirati)”<\/strong>Randomized phase 3 study in patients with active NSCLC after 1 line of chemotherapy and immunotherapy, evaluating Sitravatinib in combination with Nivolumab, versus Docetaxel ” – TROPION-Lung01 – DS1062-A-U301 (DAIICHI SANKYO)”<\/strong> Randomized phase 3 study in patients with NSCLC without oncogenic mutations, evolving after 1 line of chemotherapy and immunotherapy, evaluating DS1062-A versus Docetaxel.” – ACT16849 (SANOFI)<\/strong> “A multi-centre, non-randomised, open-label, multi-cohort, phase 2 study evaluating the clinical benefit of SAR444245 (THOR-707) in combination with other cancer therapies for the treatment of patients with lung cancer or pleural mesothelioma.” – D5084C00007 – SAVANNAH (AstraZeneca)<\/strong>“Study of osimertinib plus savolitinib in patients with EGFR-mutated and MET-amplified non-small cell lung cancer after osimertinib.” – NAVIGATE (BAYER)”<\/strong> Phase 2 Basket study evaluating Larotrectinib in tumors with NTRK fusion” – DS1062-A-U202 TROPION-Lung05 (DAIICHI SANKYO)”<\/strong> Multicenter, randomized, phase 2, open-label study evaluating DS-1062a in oncogenically-addictive NSCLC progressing with a TKI and a platinum-based chemotherapy line +\/- immunotherapy ” – DS8201-A-U206 DESTINY Lung02 (DAIICHI SANKYO)”<\/strong>Multicenter, Randomized Phase 2 Study Evaluating Trastuzumab Deruxtecan in Patients with HER2-Mutated Locally Advanced or Metastatic NSCLC <\/p>\n – MS201923-0050 (MERCK\/IQVIA)”<\/strong> Open-label, single-arm, Phase 2 study evaluating topotecan in combination with berzosertib (M6620) in patients with platinum-resistant small cell lung carcinoma ” – ACT16849 (SANOFI)<\/strong> “A multi-centre, non-randomised, open-label, multi-cohort, phase 2 study evaluating the clinical benefit of SAR444245 (THOR-707) in combination with other cancer therapies for the treatment of patients with lung cancer or pleural mesothelioma.” THASSOS<\/strong> (ASTRAZENECA) Real-life study of early-stage NSCLC: prevalence of EGFR mutations, treatment and outcomes<\/p>\n TERAVOLT<\/strong> \u2013 Covid and Cancer<\/p>\n CBP-COVID (CH le Mans)<\/strong> Impact of lockdown and preventive measures during SARS-COV2 infection on the clinical profile, diagnostic and therapeutic management and prognosis of patients with lung cancer: a study over two time periods “<\/p>\n COFAC-1 (Nantes University Hospital)<\/strong> – Multicenter, retrospective cohort study of factors associated with real-life choice of 1st line metastasis in patients with PD-L1\u226550% advanced NSCLC<\/p>\n THE BREATHE Cohort (Nantes University Hospital)<\/strong> – Single-center prospective cohort study of patients with metastatic bronchopulmonary carcinoma associated with a biocollection<\/p>\n<\/div>\n Pulmonary arterial hypertension in adults (national center of competence)<\/p>\n<\/div>\n Severe respiratory failure with devices.<\/p>\n<\/div>\n Cystic fibrosis in adults (national reference center)<\/p>\n<\/div>\n – ABBVIE M19530:<\/strong>Therapeutic protocol for patients homozygous for the F508del mutation – Non-Tuberculous Mycobacteria<\/strong>: Epidemiology and Clinical Features of Non-Tuberculous Mycobacterial Infections in Patients with Cystic Fibrosis Tuberculosis and non-tuberculous mycobacterial diseases<\/p>\n<\/div>\n -Non-Tuberculous Mycobacteria:<\/strong> Epidemiology and Clinical Features of Non-Tuberculous Mycobacterial Infections in Patients with Cystic Fibrosis – Mycobacterium avium complex pulmonary infections:<\/strong> Infectious diseases<\/p>\n<\/div>\n –Chronic pulmonary aspergillosis<\/strong>“Comparison of the efficacy at six months of a combination of itraconazole and nebulized Ambisome\u00ae versus itraconazole alone”: Adult patients with chronic pulmonary aspergillosis – Legionellosis:<\/strong> Bacterial and human biomarkers of prognostic interest for severe legionellosis –Bronchiectasis (excluding cystic fibrosis) with chronic infection by Pseudomonas aeruginosa:<\/strong>“Evaluation of the efficacy and safety of a 12-month inhaled treatment with colistimethate sodium – Antibiotic therapy in patients with mechanically acquired tracheobronchitis: hospitalized patients older than 18 years Interstitial lung disease \/ sarcoidosis<\/p>\n<\/div>\n -Idiopathic Pulmonary Fibrosis:<\/strong> “Pulse Oscillometry for Monitoring Idiopathic Pulmonary Fibrosis”: Patients over 45 years old -Dose reduction strategies in thoracic sarcoidosis imaging: patients older than 18 years followed for thoracic sarcoidosis Pulmonary and cardiopulmonary transplantation<\/p>\n<\/div>\n -PRELUD: Cohort of lung and cardiopulmonary transplant patients followed for 3 years post-transplant: “Prediction of chronic lung allograft dysfunction after lung transplantation”<\/p>\n https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03967340?term=prelud&cntry=FR&draw=2&rank=1<\/a><\/p>\n<\/div>\n Invasive or non-invasive ventilation<\/p>\n<\/div>\n –Non-invasive ventilation:<\/strong>“Evaluation of respiratory assistance in patients with chronic obstructive pulmonary disease (COPD) after an acute exacerbation”: Adult patients hospitalized for an exacerbation of their COPD![\"\"](\"https:\/\/lungo2.fr\/wp-content\/uploads\/2022\/06\/equipe-2022-3-300x189.jpg\")
The pulmonary research team, from left to right:<\/em><\/p>\n\n
![\"\"](\"https:\/\/lungo2.fr\/wp-content\/uploads\/2021\/11\/photo-recherche-clinique-300x144.jpg\")
<\/p>\n\n
\n
\n
The research activity of the department consists of:<\/h2>\n
\n
\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT04049175?term=PERSEA&cond=severe+asthma&draw=2&rank=1<\/a><\/p>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03325088?term=naracas&cond=severe+asthma&draw=2&rank=1<\/a><\/p>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02911220?term=GANA&cond=asthma&draw=2&rank=1<\/a><\/p>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT04565483?term=BENRAPRED&draw=2&rank=1<\/a><\/p>\n<\/div>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT04039113?term=COURSE&cond=COPD&cntry=FR&draw=2&rank=1<\/a><\/p>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03890224?term=rescue+2&cond=copd&cntry=FR&draw=2&rank=1<\/a><\/p>\n<\/div>\n\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT04026412?term=CA209-73L&draw=2&rank=1<\/a><\/p>\n\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03977194<\/a><\/p>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT04475939?term=ZEAL1%2F+213400+%28GSK%29&draw=2&rank=1<\/a><\/p>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03970746?term=PDC-Lung-101&draw=2&rank=1<\/a><\/p>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT04914897<\/a><\/p>\n
\nwith metastatic squamous or non-squamous non-small cell lung cancer.”<\/p>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT04746924<\/a><\/p>\n\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT04487080?term=MARIPOSA+%2F73841937NSC3003+%28JANSSEN%29&draw=2&rank=1<\/a><\/p>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT04538664?term=PAPILLON+%2F+JRD+61186372NSC3001+%28JANSSEN%29&draw=2&rank=1<\/a><\/p>\n\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT04154956?term=EFC15858+%2F+CARMEN-LC03+%28SANOFI%29&draw=2&rank=1<\/a><\/p>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03334617?term=HUDSON&draw=2&rank=1<\/a><\/p>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03906071?term=SAPPHIRE+%28Mirati%29&draw=2&rank=1<\/a><\/p>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT04656652?term=TROPION-Lung01+-+DS1062-A-U301+%28DAIICHI+SANKYO%29&draw=2&rank=1<\/a><\/p>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT04914897<\/a><\/p>\n\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03778229?term=SAVANNAH&draw=2&rank=1<\/a><\/p>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02576431?term=NAVIGATE+%28BAYER%29&draw=2&rank=2<\/a><\/p>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT04484142?term=DS1062-A-U202+TROPION-Lung05+%28DAIICHI+SANKYO%29&draw=2&rank=1<\/a><\/p>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT04644237?term=DS8201-A-U206+DESTINY+Lung02+%28DAIICHI+SANKYO%29&draw=2&rank=1<\/a><\/p>\n\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT04768296?term=berzosertib&draw=2&rank=1<\/a><\/p>\n\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT04914897<\/a><\/p>\n\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03969888?term=abbvie+m19-530&draw=2&rank=1<\/a><\/p>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03312075?term=cystic+fibrosis&cond=Non-Tuberculous+Mycobacterial+infection&draw=2&rank=8<\/a><\/p>\n<\/div>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03312075?term=cystic+fibrosis&cond=Non-Tuberculous+Mycobacterial+infection&draw=2&rank=8<\/a><\/p>\n
\n“CLArithromycin versus AZIthromycin in the treatment of Mycobacterium avium complex pulmonary infections”.
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03236987?term=CLAZI&draw=2&rank=1<\/a><\/p>\n<\/div>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03656081?cond=Chronic+Pulmonary+Aspergillosis&draw=2&rank=1<\/a><\/p>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03064737?term=PROGLEGIO&draw=1&rank=1<\/a><\/p>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03460704?term=zambon&cond=Bronchiectasis&draw=2&rank=1<\/a><\/p>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03012360?term=TAVEM2&cntry=FR&draw=2&rank=1<\/a><\/p>\n<\/div>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03898284?term=oscillo+fibrose&cond=Fibrosis&cntry=FR&draw=2&rank=1<\/a><\/p>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03140644?cond=Sarcoidosis%2C+Pulmonary&cntry=FR&draw=2&rank=1<\/a><\/p>\n<\/div>\n
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03890224?term=rescue+2&cond=copd&cntry=FR&draw=2&rank=1<\/a>
\n– High-Flow Oxygen Therapy<\/strong>: “Incidence of Nasal High-Flow Oxygen Therapy Use in Patients Hospitalized in the Intensive Care Unit”
\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT04141956?term=ohe+rea&cntry=FR&draw=2&rank=1<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"